FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with a RET Mutation By Ogkologos - November 6, 2024 600 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LIBRETTO-531 study Source RELATED ARTICLESMORE FROM AUTHOR Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance Aiming to Prevent Cancer Cases, ESMO Calls Against Misleading Alcohol-Labelling Following European Parliament Vote on the EU Wine Package ESMO Call for Cancer Care Safeguards Reflected in the EU’s Health Crisis Preparedness Plan MOST POPULAR What to Say to Someone With Cancer: A Patient Perspective July 14, 2022 Efficacy and Safety of Trastuzumab and Pertuzumab in Combination with FLOT... June 21, 2022 Deaf Football Team Makes History, Heads To School’s First Finals Game... November 24, 2021 NCI Launches New Resource for Specimens and Data from Cancer Clinical... April 2, 2018 Load more HOT NEWS Emergency presentations: what are they, and what do they mean for... The Cancer Moonshot: A Midpoint Progress Update FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive Stage Small Cell... Do as I say, not as I do – when the...
